Daiken Biomedical announced that its consolidated revenue for June reached NT$175 million, a 93.35% increase compared to the same period last year. The company’s cumulative revenue from January to June grew 50.57% year-on-year. Concurrently, Daiken unveiled its “Seven Strategic Engines” international expansion blueprint, aiming to establish itself as Asia’s most promising health technology brand.

To deepen its long-term competitiveness, Daiken has launched the “Seven Strategic Engines” covering seven key domains: Big Health, Big E-commerce, Big Data, Big AI, Big Market, Big M&A, and Big Growth. Through vertical integration and international partnerships, the company strives to build a comprehensive health technology operational ecosystem.

Chairman Zhang Jia-Ming stated that Daiken is a health technology enterprise combining clinical evidence, data application, AI intelligence, and cross-border e-commerce channels. Headquartered in Taiwan with active expansion in Asia, Daiken aims to become a key global brand in the health industry chain.

In the areas of Big Health and Big E-commerce, Daiken continues to focus on best-selling supplements such as fish oil, lutein, and bitter melon peptides, while investing in the development of clinically promising products including GLP-1/GIP dual-mechanism weight management formulas, exosome-based beauty and skincare products, and SIRT1-activating anti-aging compounds to realize an all-age health vision. Simultaneously, the company is strengthening direct-to-consumer (D2C) e-commerce systems in Taiwan, Japan, and Australia, integrating AI recommendation technology and marketing automation to create a high-conversion operational model.

For Big Data and Big AI, Daiken integrates health questionnaires, consumer behavior, and clinical trial data to build its proprietary Daiken Health Data Lake. The company is actively developing an “AI Nutritionist App” that combines wearable device data, guided health consultations, and nutrition management functions. This platform will expand to corporate health management and other applications to construct a complete health ecosystem.

In its Big Market strategy, Daiken targets high-end consumer markets in Japan, Australia, and Southeast Asia. According to international research data, the 2024 functional and health supplement markets are valued at over NT$1 trillion in Japan, approximately NT$446.8 billion in Australia, NT$238 billion in Southeast Asia, and about NT$170 billion in Taiwan. Daiken’s total revenue in 2024 is forecasted at NT$1.3 billion, accounting for less than 1% of Taiwan’s health food market share. The company plans to deepen its presence in these high-potential markets to capture greater market share across the Asia-Pacific region.

Regarding Big M&A, Daiken adheres to value investing principles by focusing on core market consolidation and international market deployment. For its Big Growth objective, the company employs a three-axis evaluation framework centered on high revenue growth, strong profitability growth, and vigorous M&A momentum to build future operational growth potential.

Resource: 大研生醫6月營收年增逾9成 ７大戰略引擎佈局